Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 12Tumor-Agnostic 3Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Neoplasms 3

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × napabucasin × Tumor-Agnostic × Clear all
NCT01775423 2023-11-14

A Study of BBI608 in Adult Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.

Phase 1 Completed
87 enrolled
Tumor-Agnostic

Neoplasms

NCT02467361 2023-11-14

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

Sumitomo Pharma America, Inc.

Phase 1 Completed
104 enrolled
Tumor-Agnostic

Neoplasms

NCT02432326 2023-11-08

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Sumitomo Pharma America, Inc.

Phase 1 Completed
147 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡